Dissemin is shutting down on January 1st, 2025

Published in

American Association for Cancer Research, Clinical Cancer Research, 22(13), p. 6549-6554, 2007

DOI: 10.1158/1078-0432.ccr-07-1088

AACR Education book, 1(2008), p. 397-406

DOI: 10.1158/aacr.edb-ccr-07-1088

Links

Tools

Export citation

Search in Google Scholar

Therapeutic Implications of Leukemic Stem Cell Pathways

Journal article published in 2007 by Saranya Chumsri, William Matsui ORCID, Angelika M. Burger
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract An emerging concept in cancer biology is that a rare population of cancer stem cells exists among the heterogeneous cell mass that constitutes a tumor. This concept is best understood in human myeloid leukemia. Normal and malignant hematopoietic stem cell functions are defined by a common set of critical stemness genes that regulate self-renewal and developmental pathways. Several stemness factors, such as Notch or telomerase, show differential activation in normal hematopoietic versus leukemia stem cells. These differences could be exploited therapeutically even with drugs that are already in clinical use for the treatment of leukemia. The translation of novel and existing leukemic stem cell–directed therapies into clinical practice, however, will require changes in clinical trial design and the inclusion of stem cell biomarkers as correlative end points.